Wolfram syndrome (WFS) type 1 is a monogenic disorder with autosomal
recessive inheritance caused by mutations in WFS1, a gene
(location 4p16.1) associated with endoplasmic reticulum function in
neuronal and endocrine cells [1]. WFS is also known as DIDMOAD syndrome
and is characterised by Diabetes insidipus (DI), Diabetes mellitus (DM),
Optic atrophy (OA), and Deafness (D). Here, we report 5 unrelated Indian
children presenting to us over the last 2 years with a referral
diagnosis of type 1 diabetes mellitus (T1DM), subsequently diagnosed to
have DIDMOAD syndrome. We also highlight atypical presentations and
early pointers to the disease.
A 9-year-old girl was diagnosed to have T1DM 2 years
back and was on insulin therapy. She presented with decreased visual
acuity and polyuria (urine output 4 L/day) that persisted despite good
glycemic control. On evaluation, urine osmolality was 158 mosmol/L and
serum osmolality was 302 mosmol /L. Urine osmolality increased to 280
mOsm/L with intravenous vaso-pressin suggestive of central DI. Magnetic
resonance imaging (MRI) brain revealed an absent pituitary bright spot.
Detailed evaluation revealed hydroureteronephrosis, neurogenic bladder,
bilateral optic atrophy and bilateral moderate sensorineural hearing
loss. Direct sequencing of WFS1 gene by Sanger method, revealed a
novel homozygous variant frame shift mutation c.2486_2489dupTGGA
(p.Glu830Asp*111) in exon 8. She was managed with oral desmopressin
tablets, clean intermittent urinary catherization and continued on
insulin therapy.
Five patients (3 males) with WFS type 1 were
identified with the mean (SD) age of 11 (2) years. There was no family
history or consanguinity in the parents. All patients had DM and OA. DI
was present in 4 patients and hearing impairment and urological
abnormalities in 3 patients each. All cases had normal stature except
one, and all were pre-pubertal except case 3. Case 3 presented at 13
years with DM since 4 years, polyuria (despite adequate glycemia) and
visual problems. Eye examination revealed optic atrophy and glaucoma.
She was diagnosed to have central DI and started on desmopressin. On
follow-up, she had delayed puberty (absent menarche till 16 years with
SMR stage 3). The baseline gonadotropin levels were LH 1.09 mIU/mL and
FSH 6.37 mIU/mL, and levels post-GnRH stimulation LH 20.6 mIU/mL and FSH
28.6 mIU/mL.
Thyroid function tests were done in all children and
were found to be within normal limits. Case 3 reported compound
heterozygous missense/frameshift mutation in exons 4/8
c.397G>A/c.1234_1237delGTCT (p.A133T/p.V412Sfs29). Case 2 revealed a
homozygous deletion Exon 8 c.1525_1539 del15 (p.V509_Y513del) on genetic
analysis by Sanger method and Case 4 revealed a novel homozygous variant
missense mutation Exon 8 c.1372G>A (p.A458T). No mutation was identified
in Case 5.
WFS is a rare neuro-degenerative autosomal recessive
disease that was first described in 1938 [2]. Its prevalence was
estimated to be 1 in 68,000 to 1 in 770,000 [2,3]. Apart from these
common manifestations, screening for urological and psychological
abnormalities, and endocrine disorders is paramount, as they often
remain unnoticed, adding to disease morbidity. The minimum diagnostic
criteria of WFS are the coincidence of early-onset DM and OA [2]. There
is no effective treatment for this neurodegenerative disease with
reports suggesting a median life expectancy of 30 years [2]. Death
usually occurs from respiratory failure as a result of brain stem
atrophy.
DM is usually the first manifestation of the disease.
A multicentric study conducted by Rohayem, et al. [4] described notable
differences between the diabetes of WFS and TIDM including earlier
median age of onset of diabetes, less incidence of diabetic ketoacidosis
at onset, a much lower insulin requirement, rare micro-vascular
complications, and absence of autoantibodies in the former. The mean
(SD) age of diagnosis of DM in our study was 8.2 years (2) with none of
patients having diabetic ketoacidosis at presentation.
Diabetes insipidus appears at an average age of
14 years and affects approximately 70% of patients [3]. About 80% of the
patients in our study had DI, which is consistent with the literature.
The diagnosis is often delayed as polyuria and polydipsia are
overlapping symptoms of both DI and DM.
Patients with WFS demonstrate progressive optic
atrophy that usually occurs after diagnosis of DM. Other ophthalmo-logical
findings reported are colour vision deficits, cataract and pigmentary
retinopathy [5]. All patients in our case series had optic atrophy,
whereas glaucoma and cataract were present in two and one patient,
respectively.
Bladder dysfunction in children and young adults with
WFS is common and easily missed (only 30% symptomatic), and can be
initial presenting feature as was seen with two of our cases. Structural
and functional urinary tract abnormalities are commonly seen including
atonic bladder, bladder-sphincter dyssynergia, hydro-ureteronephrosis,
and recurrent urinary tract infections [6].
Patients with DIDMOAD have been reported to have
growth failure due to defects in hypothalamic pituitary function [6] and
hypogonadism, therefore follow-up of these patients is essential.
Neurological complications generally appear in later life at a median
age of 30 yrs (range 5-44yrs) and include truncal ataxia, loss of gag
reflex, myoclonus, epilepsy, peripheral neuropathy and central apnea
[1]. Psychiatric manifestations including depression, psychosis and
aggression are also common and should be screened for.
In conclusion, our case series highlights a lack of
awareness among physicians about this entity, culminating into under and
delayed diagnosis of this disorder. There is a need to have a high index
of suspicion for the diagnosis of DIDMOAD syndrome in patients with T1DM
presenting with other systemic involvement. Patients with DIDMOAD should
be screened for other associated problems and require multi-disciplinary
care [6]. Since this is a neurodegenerative disorder with poor
prognosis, it is prudent to provide appropriate genetic counselling and
offer prenatal diagnosis for prevention in future pregnancies.
Funding: Cost of sequencing was funded by Indian
Council for Medical Research (ICMR), New Delhi, India.
1. Çelmeli G, Türkkahraman D, Çürek Y, et al.
Clinical and molecular genetic analysis in three children with Wolfram
syndrome: A novel WFS1 mutation (c.2534T>A). J Clin Res Pediatr
Endocrinol. 2017;9:80-84.
2. Wolfram DJ. Diabetes mellitus and simple optic
atrophy among siblings. Mayo Clin Proc. 1938;13:715-18.
3. Barrett TG, Bundey SE, Macleod AF.
Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD)
syndrome. Lancet. 1995;346:1458-63.
4. Rohayem J, Ehlers C, Wiedemann B, et al. Diabetes
and neurodegeneration in Wolfram syndrome: A multicenter study of
phenotype and genotype. Diab Care. 2011;34:1503-10.
5. Al-Till M, Jarrah NS, Ajlouni KM. Ophthalmologic
findings in fifteen patients with Wolfram syndrome. Eur J Ophthal.
2002;12:84-8.
6. Simsek E, Simsek T, Tekgu S, et al. Wolfram
(DIDMOAD) syndrome: A multidisciplinary clinical study in nine Turkish
patients and review of the literature. Acta Paediatr. 2003;92:55-61.